Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

29.23 UNCHANGED
Delayed Quote Updated: 7:00 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock ↗
This surprising healthcare stock has been outperforming the markets this year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Medicus Pharma (MDCX) Q3 2026 Earnings Call Transcript ↗
A SkinJect SPAC plan and melanoma focus mark the next phase. 
Via The Motley Fool
Topics Earnings
Most-Active S&P 500 Stocks in Today's Session ↗
Via Chartmill
Topics Stocks
News headline image
Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028 ↗
Investors shouldn't count out Pfizer in the GLP-1 market just yet. 
Via The Motley Fool
Pfizer (NYSE:PFE) Beats Q3 2026 Estimates and Raises Full-Year Outlook as New Products Offset COVID Declines ↗
Via Chartmill
News headline image
6th Annual Sickle Cell Caregiver Summit Brings Global Voices Together to Strengthen Families, Advocacy, and Caregiver Wellness
November 8, 2026 -- November 13–15 Virtual Event Connects Caregivers, Healthcare Professionals, and Advocates Across Borders 
Via 24-7 Press Release
News headline image
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials ↗
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too. 
Via The Motley Fool
News headline image
After the Midterm Rally, the Dow Is on Track to Beat the Nasdaq for the First Time Since 2022. Here's What History Says Could Come Next. ↗
The Dow tends to outperform the Nasdaq during growth stock-driven sell-offs. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
S&P 500 Most-Active Stocks Today: Oracle Leads Volume, Microchip Drops 11.56% ↗
Via Chartmill
Topics Stocks
News headline image
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market ↗
They are so much more than just dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 3% year on year to $68... 
Via StockStory
News headline image
3 value stocks we think twice about
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q3 2026, with revenue up 39.2% year on ... 
Via StockStory
Most Active S&P 500 Stocks: Marvell, Oracle, Ford Lead Nov. 5 Trading ↗
Via Chartmill
Topics Stocks
News headline image
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? ↗
Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect. 
Via The Motley Fool
Topics Intellectual Property
Most-Active S&P 500 Stocks for Nov. 4, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
Pfizer: 3 Key Takeaways for Long-Term Investors ↗
The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Pfizer Q3 Earnings Call Highlights ↗
Pfizer (NYSE:PFE) reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and... 
Via MarketBeat
Topics Earnings
News headline image
PFE Q3 deep dive: new product momentum offsets margin compression, guidance raised for 2026
Global pharmaceutical company Pfizer (NYSE:PFE) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales were flat year on year at $16.58 b... 
Via StockStory
News headline image
AMRX Q3 deep dive: biosimilars and specialty launches expand growth engines, guidance raised
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 10% year on ye... 
Via StockStory
News headline image
Earnings to watch: Zoetis (ZTS) reports Q3 results tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu... 
Via StockStory
Topics Artificial Intelligence
News headline image
Collegium Pharmaceutical (COLL) Q3 earnings: what to expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should... 
Via StockStory
Topics Artificial Intelligence
News headline image
Pfizer (PFE) Q3 2026 Earnings Call Transcript ↗
Pfizer lifts guidance as newer drugs grow, even as COVID sales keep falling. 
Via The Motley Fool
Topics Earnings
Most Active S&P 500 Stocks: Oracle, Palantir, Marvell Lead Nov. 3 Volume ↗
Via Chartmill
Topics Stocks
News headline image
BioNTech Q3 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the... 
Via MarketBeat
Topics Earnings
News headline image
Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction ↗
Pfizer's revenue didn't grow, but the mix underneath it changed a lot. 
Via The Motley Fool
News headline image
Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally? ↗
The healthcare stock may finally have the catalyst that it needs to take off before the end of the year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Hikes Guidance On Solid Third Quarter, Names Company Vet As New CFO ↗
Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO. 
Via Investor's Business Daily
News headline image
Pfizer (NYSE:PFE) reports strong Q3 2026, full-year outlook slightly exceeds expectations
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q3 2026 results exceeding the market’s revenue expectations, but revenue was flat year on year at $1... 
Via StockStory
News headline image
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.